Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03139812Phase 4Completed
Phase 4, randomised, open-label trial (2 arms), sponsored by University of California, Berkeley. Primary endpoints: Corneal epithelial permeability at 30 days and Risk of adverse events at 30 days. Started Jan 2012; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03139812.